Treatment of reflux in infants: clinical results with Reflucalm
Gastroesophageal reflux in infants is a common condition characterized by frequent regurgitation, inconsolable crying, sleep disturbances, and feeding difficulties. When persistent, these symptoms can cause significant stress for parents and impact the infant’s overall well-being.
Reflucalm is a medical device specifically designed for the treatment of reflux in newborns. Its natural, safe, and side effect–free formulation has been evaluated through a multicenter observational clinical study.
Clinical Study: Methodology and Results in Infants
The study involved 20 infants treated with Reflucalm for 4 weeks. The efficacy was assessed using the I-GERQ-R questionnaire (Infant Gastroesophageal Reflux Questionnaire Revised), a validated clinical tool for measuring reflux-related symptoms in infants.
Parameters evaluated included regurgitation, crying, irritability, apnea episodes, and feeding difficulties.
Clinical Results in Newborns
After 4 weeks of treatment, the average I-GERQ-R score dropped from 24.75 to 9.5, with a mean reduction of 15.25 points (p<0.001). All patients experienced a ≥50% reduction in symptoms, with notable improvements in behavior, sleep quality, and feeding.
Reflucalm was well tolerated and safe in all treated infants, making it a valid and natural solution for managing reflux-related digestive disorders in newborns.
Why Choose Reflucalm for Infants?
- Reduces regurgitation and crying
- Safe and free from side effects
- Improves sleep and appetite
- Suitable from birth
Looking for a B2B-ready or private label solution?
We are certified manufacturers of medical devices, dietary supplements, and cosmetics. Reflucalm is ready for market entry or private labeling, with full regulatory and clinical support.
